Sort by
Items per page

Send to

Choose Destination

Best matches for GLATIRAMER/PD:

Search results

Items: 1 to 20 of 88


The Novel Effect of Immunomodulator-Glatiramer Acetate on Epileptogenesis and Epileptic Seizures.

Lai MC, Lin KM, Yeh PS, Wu SN, Huang CW.

Cell Physiol Biochem. 2018;50(1):150-168. doi: 10.1159/000493965. Epub 2018 Oct 2.


[Effect of preventive treatment on cognitive performance in patients with multiple sclerosis].

Shorobura MS.

Wiad Lek. 2018;71(3 pt 2):648-652. Ukrainian.


Corpus callosum demyelination associated with acquired stuttering.

Decker BM, Guitar B, Solomon A.

BMJ Case Rep. 2018 Apr 21;2018. pii: bcr-2017-223486. doi: 10.1136/bcr-2017-223486.


Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.


Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosis.

Eilam R, Segal M, Malach R, Sela M, Arnon R, Aharoni R.

Glia. 2018 May;66(5):1098-1117. doi: 10.1002/glia.23304. Epub 2018 Feb 9.


Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.

Omura S, Sato F, Martinez NE, Range T, Ekshyyan L, Minagar A, Alexander JS, Tsunoda I.

Arch Virol. 2018 May;163(5):1279-1284. doi: 10.1007/s00705-018-3729-6. Epub 2018 Jan 23.


Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.

Ludwig MD, Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2018 Feb;243(4):361-369. doi: 10.1177/1535370217749830. Epub 2018 Jan 7.


[Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].

Boyko AN, Alifirova VM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(11):135-139. doi: 10.17116/jnevro2017117111135-139. Review. Russian.


Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, Krispin R, Papir G, Sahly Y, Hayden MR.

Ann N Y Acad Sci. 2017 Nov;1407(1):75-89. doi: 10.1111/nyas.13547.


Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.


Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.

Williams MJ, Johnson K, Trenz HM, Korrer S, Halpern R, Park Y, Herrera V.

Curr Med Res Opin. 2018 Jan;34(1):107-115. doi: 10.1080/03007995.2017.1374937. Epub 2017 Oct 3.


Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.

Br├Žnne I, Zeng L, Willenborg C, Tragante V, Kessler T; CARDIoGRAM Consortium; CARDIoGRAMplusC4D Consortium, Willer CJ, Laakso M, Wallentin L, Franks PW, Salomaa V, Dehghan A, Meitinger T, Samani NJ, Asselbergs FW, Erdmann J, Schunkert H.

PLoS One. 2017 Aug 22;12(8):e0182999. doi: 10.1371/journal.pone.0182999. eCollection 2017.


Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms.

Corey-Bloom J, Aikin AM, Gutierrez AM, Nadhem JS, Howell TL, Thomas EA.

Brain Res. 2017 Oct 15;1673:102-110. doi: 10.1016/j.brainres.2017.08.013. Epub 2017 Aug 18.


Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.

Ozakbas S, Cinar BP, Kosehasano─čullari G, Kahraman T, Oz D, Kursun BB.

Clin Neurol Neurosurg. 2017 Sep;160:69-72. doi: 10.1016/j.clineuro.2017.06.016. Epub 2017 Jun 27.


Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.


Two decades of glatiramer acetate: From initial discovery to the current development of generics.

Weinstock-Guttman B, Nair KV, Glajch JL, Ganguly TC, Kantor D.

J Neurol Sci. 2017 May 15;376:255-259. doi: 10.1016/j.jns.2017.03.030. Epub 2017 Mar 21. Review.


Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.

Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.

J Comp Eff Res. 2017 Jun;6(4):313-323. doi: 10.2217/cer-2016-0085. Epub 2017 Mar 28.


Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL.

Eur J Neurol. 2017 May;24(5):726-733. doi: 10.1111/ene.13272. Epub 2017 Mar 22.


A Potential Life-Threatening Reaction to Glatiramer Acetate in Rett Syndrome.

Nissenkorn A, Kidon M, Ben-Zeev B.

Pediatr Neurol. 2017 Mar;68:40-43. doi: 10.1016/j.pediatrneurol.2016.11.006. Epub 2016 Dec 7.


Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia.

Ahn YH, Jeon SB, Chang CY, Goh EA, Kim SS, Kim HJ, Song J, Park EJ.

Sci Rep. 2017 Jan 17;7:40484. doi: 10.1038/srep40484.

Supplemental Content

Loading ...
Support Center